Addtech acquires Mediplast AB and prepares for a separate listing of the Life Science business area on NASDAQ OMX Stockholm

Life Science, a business area in the Addtech Group, has today signed an
agreement to acquire all shares in Mediplast AB.

Mediplast AB is the parent company of the Mediplast Group and is a leading
Nordic supplier of medical technology equipment and consumables. The company has
its head offices in Malmö and pursues operations via its own trading companies
in Sweden, Denmark, Finland, Norway and the Netherlands. Mediplast also has its
own production facilities in Denmark, Finland and Italy. The company holds a
strong position in the Nordic countries and markets both its own products as
well as those of leading suppliers in the areas of surgery, intensive care,
thorax/neuro, ENT and ostomy care. Mediplast’s customers operate in both the
private and public sectors. In the 2014 financial year, the Mediplast Group
generated sales totalling approximately SEK 465 million, an operating profit
before amortisation of intangible assets (EBITA) of around SEK 45 million and
had roughly 120 employees.

The acquisition of Mediplast marks an important entry into the field of medical
technology for the Life Science business area, and it will form the basis of the
newly established Medical Technology business unit. The acquisition is expected
to take effect at the beginning of July. The total purchase consideration of the
acquisition of Mediplast amounts to approximately SEK 480 million. It is
estimated that the acquisition will have a positive effect on Addtech’s earnings
per share during the current financial year.

The Board of Directors of Addtech has decided to initiate the process of a
separate listing on NASDAQ OMX Stockholm by distributing the shares in the Life
Science’s operations to Addtech’s shareholders. The ambition is to carry out the
listing in the first half of 2016.

During the course of the past ten years that Life Science has been part of
Addtech, the business area has developed and broadened its product range, while
increasing its sales from around SEK 450 million to roughly SEK 1,050 million,
with healthy profitability. Growth is a result of a combination of solid organic
growth and acquisitions of profitable companies. Life Science is today one of
the leading independent suppliers in the Nordic region on its markets and the
addition of Mediplast will mean that sales will exceed SEK 1,500 million.

“The motive for a separate listing is that Life Science has achieved a size and
level of profitability that makes the business attractive as an independent,
listed company. This was an idea already before Addtech was distributed to the
shareholders of the Bergman & Beving Group back in 2001. As a listed company,
Life Science will be able to continue to grow via new operations and
acquisitions,” says Johan Sjö, Addtech’s President and CEO.

Of the total purchase consideration for Mediplast, roughly 50 percent will be
paid in cash and 50 percent through an issue in kind in the parent company that
owns the companies in Addtech’s Life Science business area. The current
principal owner of the Mediplast Group, Roos Gruppen AB, will together with two
Mediplast managers own 15 percent in the parent company of the Life Science
business.

“I’m very positive about this deal and look forward to having the opportunity to
continue following Mediplast’s development in this new structure. Life Science
is in an excellent position to continue to have good growth with profitability,”
says Håkan Roos, Chairman of Roos Gruppen AB.

Lars-Erik Rydell, Managing Director of the Mediplast Group, comments: “I’m
extremely satisfied with Addtech as new owner, as the companies share the same
values and together with Mediplast’s personnel I look forward to our future
cooperation, which will enable continued expansion in the field of medical
technology.”

Stockholm, 4 June, 2015

Addtech AB (publ)

For further information, please contact
Johan Sjö, President, Addtech AB, +46 8 470 49 00